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Abstract
To maintain adequate cerebral blood flow despite frequent chang-
es in systemic arterial blood pressure and to constantly adjust blood
supply to the current metabolic demand dictated by neuronal elec-
trical activity, brain developed a myriad of mechanisms. These are
designed to protect central nervous system from fatal consequenc-
es of hypoxia and energy deficit and are collectively called “cere-
bral autoregulation”. Despite years of research mechanisms respon-
sible for regulation of CBF functioning under physiologic and patho-
logic conditions are still not clear. When these mechanisms are
damaged or exhausted, patients life is in danger, as even slight,
negligible under normal conditions, systemic hemodynamic distur-
bances might lead to cerebral infarct. Even perfect imaging of the
irreversible brain damage with MR for the particular patient is too
late action. Thus, detection of cerebral blood flow disturbances and
impaired autoregulation, which are known to be associated with
high risk of stroke, are extremely important in clinical practice. Se-
veral methods have been developed to quantify this process and
thus evaluate risk of cerebral ischemia and guide therapeutic pro-
cess. This review focuses on current knowledge on physiology of
regulation of cerebral blood flow, mechanisms responsible for brain
damage resulted from cerebral ischemia and reviews noninvasive
diagnostic tests to assess cerebral autoregulation.
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Cerebral blood flow regulation
Brain tissue constantly maintains an extremely high metabolic
rate. Cerebral oxygen consumption (ª 3.5 ml/100g tissue/min)
[1] accounts for about 20% resting total body oxygen consump-
tion. The metabolic demand must be matched by high blood flow
supply, which on average exceeds 50 ml/100g tissue/min, ac-
counting for 15–20% of the total cardiac output [1, 2]. As the brain
almost exclusively uses glucose for its energy metabolism and in
general does not store energy, continuous blood supply, main-
tained within a narrow range, is absolutely required for brain func-
tion (90%) and cell viability (10%) [3]. Cerebral blood flow (CBF) is
driven by cerebral perfusion pressure (CPP), represented by the
difference between mean arterial blood pressure (ABP) and in-
tracranial pressure (ICP), working in concert with cerebrovascular
impedance. The components which make up cerebrovascular
impedance include:
— cerebrovascular resistance (CVR), which is inversely propor-
tional to the forth power of the vessel radius when laminar flow
occurs and the flow is in steady state;
— the internal fluid resistance, which depends on viscoelastic
properties of arterial walls, viscosity of the blood and flow ve-
locity;
— the blood inductance, which is dependent on its rheostatic
properties and momentum;
— the vascular compliance, which is related to the elasticity of
the vessel wall [4, 5].
Alteration of any of the components, which make up impe-
dance in a non steady-state system, such as occurs in the cere-
brovascular system, can significantly impact the blood flow. Mi-
crovascular constriction, however, most significantly increases the
impedance [6]. The ability of brain microvasculature to maintain
cerebral blood flow relatively constant despite wide variations in
CPP is called “cerebral autoregulation” (CA). In the normal state
CA maintains relatively constant CBF within the range of mean
ABP from about 60 to 150 mm Hg [7]. It should be mentioned,
however, that upper and lower limits of CA are not fixed and can
be shifted up or down by endogenous as well as exogenous fac-
tors. Sympathetic nervous system activity and increased levels of
Angiotensin II, for example, shift upper and lower limits of CA up
towards higher pressures, while chronic use of antihypertensive
medications have opposite effects [8, 9]. Patients with untreated
hypertension have limits of regulation set on higher level in com-
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parison to healthy people [8]. This is important because in these
patients overzealous antihypertensive treatment may lead to dan-
gerous reduction of CBF at relatively high ABP. The mechanisms
of CA are complex and not fully understood. It is surmised from
the results of numerous experimental studies that CA is maintained
by three different control pathways: vasogenic, metabolic and
neurogenic.
The vasogenic mechanism is based on the intrinsic ability of
cerebral vessels to respond to changes in shear stress and trans-
luminal pressure [10]. Increase in transluminal pressure activates
vascular smooth muscle cells leading to decrease in the diameter
of arteries [11, 12]. On the other hand, contraction of cerebral
vessels increases vascular wall shear stress [13]. This triggers
endothelial cells to release factors, that relax vascular smooth
muscles and dilates vessels [12]. These counteracting mecha-
nisms assure optimal adjustment of the vessel diameter to CPP
at any time.
The exact mechanisms of vascular contraction in response to
increase in transluminal pressure remain unclear. It appears, how-
ever, that mechanical dilation of smooth muscle cells leads acti-
vation of phospholipase C (PLC) [14]. Increased PLC activity leads
to elevated diacylglycerol levels, which activates protein kinase C,
which is known to activate nonselective cation channels, depolar-
izing the smooth muscle membrane potential and enhancing cal-
cium entry through voltage-dependent calcium channels. In-
creased concentration of free calcium ions activates the myosin
light chain kinase, which phosphorylates myosin light chains and
causes muscle contraction [15]. It is also possible that stretch of
muscle cells directly activates calcium channels and leads to in-
creased calcium concentration without activation of PLC- depen-
dent pathway [16]. In contrary to intraluminal pressure-induced
contraction, which seems to be dependent only on smooth mus-
cle cells, shear stress-induced vasodilatation requires interaction
of endothelial cells and vascular muscles. Synthesis of nitric oxi-
de (NO) is necessary for this phenomenon to occur [17]. Shear
stress increases activity of endothelial nitric synthase (eNOS) and
causes release of NO, which diffuses to adjacent smooth muscle
cells and induces vasodilatation through activation of potassium
channels in those cells [18, 19]. Shear stress may also directly
increase expression of eNOS as a shear stress-response element
has been found in promoter region of gene for eNOS [20]. It is not
clear, how significant a role the vasogenic mechanism plays in
maintaining and regulation CBF and whether it depends some-
how on caliber of the involved cerebral arteries.
In metabolic regulation, arterial resistance is modified by waste
products of energy metabolism (CO2), partial pressure of O2, and
release of specific vasoactive substances such as adenosine and
potassium ions from neurons in response to insufficient blood
supply. The most important metabolic factor is tension of CO2 in
periarteriolar space, although CVR is not directly affected by the
CO2 tension. It is the accompanying shift in periarteriolar pH, which
regulates diameter of cerebral vessels [21]. Hypercapnia and the
resulting decrease in extracellular pH causes cerebral vasodilata-
tion and increase in CBF, while hypocapnia leads to cerebral vas-
oconstriction and CBF decrease. Mechanisms responsible for
regulation of CVR by CO2 tension and accompanying pH chan-
ges are not clear. Hydrogen ions may directly activate potassium
channels in smooth muscle cells leading to its hyperpolarization
or they may induce release of vasodilatory prostaglandins, ade-
nosine or NO from neurons, glia or vessels [22–26]. Hypoxia, po-
tassium ions and adenosine also lead to hyperpolarization of
smooth muscle cells and consequently dilation of cerebral ves-
sels. It appears that hypoxia-induced vasodilatation is mediated
by activation of potassium channels, while increased concentra-
tion of potassium ions in extracellular fluid activates electrogenic
Na/K pumps and smooth muscle inward rectifier potassium chan-
nels [27, 28]. Adenosine acts on cerebral vessels through its re-
ceptors located in arterial smooth muscle membrane [29]. Acti-
vation of these receptors leads to opening of calcium-dependent
and ATP-dependent potassium channels [30, 31].
While there is a consensus that vasogenic and metabolic
mechanisms play critical role in regulation of cerebrovascular tone,
the importance of neurogenic regulation in the control of CBF is
still a matter of debate. The cerebral vessels are innervated by
extrinsic and intrinsic systems of nerve fibers. The “extrinsic” sys-
tem refers to nerve fibers originating in ganglia belonging to sym-
pathetic, parasympathetic and sensory ganglia, while nerves orig-
inating within the brain represent an "intrinsic" system [32]. Activa-
tion of sympathetic vascular nerves leads mainly to release of
norepinephrine and neuropeptide Y [33]. Sympathetic stimulation
constricts large cerebral arteries. However, CBF does not de-
crease, because the constriction of large cerebral vessels is im-
mediately compensated for by dilation of resistance arterioles [34].
The role of sympathetic innervation seems to be related to pro-
tecting the brain against ABP increases through the mechanism
of sympathetic activation shifting the upper and lower limits of CA
towards higher pressures. Parasympathetic vascular nerve fibers
release vasoactive intestinal polypeptide, acetylcholine and NO
[35, 36]. Activation of these nerves causes cerebrovascular dila-
tion, the physiological significance of which is still not clear [37].
Fibers originating in sensory ganglia contain clacitonin gene-re-
lated peptide, substance P, neurokinin A and pituitary adenylate
cyclase-activating polypeptide [38–40]. These fibers cause dila-
tation of cerebral vessels and their physiological role appears to
be counteracting action of cerebral vasoconstrictors [41]. Activa-
tion of these fibers may contribute to increase in CBF occurring in
pathologic conditions such as meningitis and may play a role in
pathogenesis of migraine [42, 43].
Vascular fibers belonging to the intrinsic system originate in
different parts of brain such as nucleus basalis, locus coeruleus
and raphe nucleus [44–46]. These fibers may modulate vascular
tone directly or through stimulation of perivascular interneurons
and glial cells [47, 48]. Activity of the intrinsic system may de-
crease or increase local blood flow depending on the rostrocau-
dal level of activation of their cells of origin within the brain. The
physiological significance of this system is not yet completely elu-
cidated [45, 46].
For academic purposes, CBF regulation is parceled into se-
veral major mechanisms, though the division is somehow artifi-
cial. The mechanisms influence and modify each other at any giv-
en time and the overall cerebrovascular tone is the product of
interplay of many processes. It is clear that some of these mech-
anisms share common biochemical pathway at the level of vas-
cular muscle cells. For instance vascular dilation caused by para-
sympathetic activation, shear stress and hypercapnia, at least in
part, are mediated by the same factor — NO [49].
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Neurovascular coupling in humans
The brain's information-processing capacity is limited by the
amount of oxygen and energy available. When neurons are ac-
tive, blood flow in that local brain region increases to meet the
enhanced local metabolic demand [50]. The tight coupling be-
tween neuronal activity and blood flow is known as the “neurovas-
cular coupling”. This phenomenon seems to be dependent on
both astrocytes and perivascular neurons.
Increased local neural activity leads to release of glutamate
acting on astrocytic metabotropic glutamate receptors [51]. Acti-
vation of glutamatate astrocytic receptors leads to increased syn-
thesis of arachidonic acid, which is metabolized to vasodilatory
prostanoids like Prostalgandin E2 (PGE2) and epoxyeicosotrienoic
acid (EET) [52, 53]. PGE2 and EET diffuse to vascular muscle
cells and dilate vessels increasing local blood flow [52, 53]. How-
ever, during this process significant amount of arachidonic reaches
vascular muscles as well. Smooth muscle cells contain enzymes
(CYP4A), which generate powerful vasoconstrictor 20-hydroxye-
icosotetraenoic acid (20-HETE) counteracting PGE2 and EET
— induced vasodilatation [48, 54]. The question arises, what shifts
this balance towards vasodilatation? Glutamate released into syn-
aptic space activates postsynaptic NMDA-type glutamate recep-
tors located on perivascular neurons [55, 56]. This leads to acti-
vation of neuronal NO synthase and production of NO, which
reaches smooth muscle cells. NO not only exerts vasodilatory ef-
fects but also binds to the heme moiety of CYP4A enzyme and
inactivates it, thereby preventing further synthesis of 20-HETE from
arachidonic acid [57, 58]. Thus activation of both nNOS positive
neurons and astrocytes seems to be necessary for proper func-
tioning of neurovascular coupling. It is likely that astrocyte-derived
vasodilatory prostanoids are direct mediators while neuronal NO
acts as a modulator of this process.
Respiratory and cardiovascular factors
and cerebral hemodynamics
Both oxygen and CO2 tension have powerful effects on car-
diovascular system through the peripheral and central chemore-
ceptors. Peripheral chemoreceptors are located in the aorta and
internal carotid artery and respond to both hypoxemia and hyper-
capnia. The peripheral chemoreflex causes hyperventilation, tran-
siently activates sympathetic traffic to peripheral blood vessels,
and increases vagal activity to the heart [59]. Activation of periph-
eral chemoreceptors does not change CBF [60]. Central chemore-
ceptors are located in ventrolateral medulla and detect pH changes
of the interstitial fluid [61]. Activation of the central chemoreceptor
reflex causes hyperventilation and increased sympathetic stimu-
lation to vasculature. Changes in sympathetic tone have a limited
effect on CBF at normal PaCO2 levels [62]. However, the sympa-
thetic nervous system seems to attenuate the CO2-induced in-
crease in CBF. This phenomenon may indicate a moderate direct
effect of the sympathetic nervous system on the cerebral vascula-
ture [62]. Sympathetic stimulation can have more important ef-
fects on segmental vascular resistance and cerebral microvascu-
lar pressure in pathologic conditions. Generalized increases in
the sympathetic discharge, causing substantial increases in ABP,
can prevent concomitant increases in CBF by acting on both small
resistance and large vessels [34, 63].
Arterial baroreceptor reflex, which plays an integral role in re-
gulating peripheral vascular tone and heart rate in response to
changes in ABP, seems to have no impact on the CBF. Neither
interruption nor stimulation of baroreceptor nerves affects CBF or
CVR at ABP within the range of CA [64, 65]. However, cerebral
vasoconstriction occurs in healthy humans during graded reduc-
tions in central blood volume. The magnitude of this response is
small compared with changes in systemic vascular resistance [66].
It seems that this degree of cerebral vasoconstriction is not by
itself sufficient to cause syncope during orthostatic stress, but
can exacerbate the decrease in CBF associated with hypoten-
sion if hemodynamic instability develops.
Cerebral ischemia and investigations
of cerebral blood flow regulation
Cerebral infarction results when blood supply is not sufficient
to support cellular viability or when low nutrients supply induces
apoptosis. The cell death is a complex function resulting from
a combination of the duration and magnitude of ischemia, the
nutrients and oxygen content of blood, the specific cerebral struc-
ture involved, and ability of the tissue to dissipate the metabolic
heat. Cell viability may be lost in as little as 20 minutes after ces-
sation of blood flow. In mild but prolonged low perfusion states,
irreversible gray matter damage will occur with CBF below ap-
proximately 20 mL/100 mg/h. Figures 1–4 demonstrate a basic
concept of chain reactions in neuron and glia cells under different
ischemic conditions, which eventually lead to cell death.
In general, ischemia results from:
— sudden arterial occlusion;
— global hypoxia due to respiratory or cardiac arrest;
— hypoperfusion in patients with high ICP;
— subacute or chronic borderline hypoperfusion due to occlu-
sion or narrowing of large cerebral arteries. The last two need
more explanation.
Cerebral blood flow disturbances in patients
with high ICP
According to the Monro-Kellie hypothesis [67] the cranium
acts as a near rigid container of virtually incompressible substances
such as brain (80%), blood (12%) and cerebrospinal fluid (CSF)
— (8%). These three volumes completely fill the intracranial cavity
and remain in a state of dynamic equilibrium with each other. Based
on these premises, any extra volume added to the intracranial
cavity will increase ICP. However, cessation of cardiac action leads
to equalization of ICP with atmospheric pressure, no matter how
high it was before stoppage of cerebral circulation. In other words,
it will always equal zero when heart does not beat. Thus, it goes
without saying that ICP is closely related to the function of cardio-
vascular system. Under normal CPP (80–100 mm Hg), ICP is not
higher than 15 mm Hg [68]. Blood pressure in the cerebral arter-
ies decreases as arterial diameter gets smaller and approaches
the interstitial tissue pressure, that is equal to ICP at the level of
brain capillaries and veins. The most significant drop in ABP oc-
curs in small resistance, and precapillary arterioles. High ABP in-
side the arterial system is not transmitted to the brain tissue be-
cause it is confined within the arteries by thick arterial walls. More-
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over, during every cardiac systole, some CSF and venous blood
is pushed out of the cranium to accommodate “cerebral” portion
of stroke volume. Thus, under normal conditions, cranial cavity
exhibits some compliance and there is only slight rise in ICP due
to distention of cerebral arteries during cardiac systole.
As mentioned before, any extra space occupying by intracra-
nial lesion is at the cost of the volume of other intracranial compo-
nents in order to maintain the ICP at normal levels. Thus, during
growth of tumors or the development of hematoma, CSF is ab-
sorbed and venous blood is pushed out of the cerebral veins to
accommodate the volume of the abnormal lesion inside the skull.
When these compensatory mechanisms are exhausted, ICP in-
creases logarithmically as pathologic volume further increases [69].
As ICP increases, the CPP and consequently CBF begin to de-
crease. From then on, the highest priority is maintaining CBF, even
at the price of further increase in ICP, as neural tissue is much
Figure 1. Physiological mechanisms of ion equilibrium in the neuron. The energy of in-flowing sodium ions is utilized for expelling the ions of calcium.
Sodium is then removed by the Na\K pump. Negative potential of the cell interior helps keep the NMDA-coupled calcium channel locked with the ions of
magnesium and inhibits the voltage-dependent calcium channels. nNOS — neuronal nitric oxide synthase, NMDA — glutamate (N-methyl-D-spartate)
receptor, ATP — adenosinotriphosphate.
Figure 2. Ischemia and consequent energy deficit cause depolarization of the cell membrane, reverses the action of the sodium-calcium exchanger and
allow influx of sodium and calcium ions into the cell. Depolarization opens the voltage-dependent calcium channels and releases magnesium-dependent
block of NMDA-coupled calcium channel. The latter is made patent by glutamate, thus leading to increased synthesis of nitric oxide. Excessive concentra-
tion of nitric oxide and calcium leads to cell death.
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Figure 3.  Biochemical mechanism of excitotoxicity. Energy deficit attenuates re-uptake of glutamate in the synaptic cleft. Increased content of this mediator
causes overstimulation of NMDA receptor, excessive synthesis of nitric oxide and influx of calcium into the cell. This leads to inactivation of mitochondrial
enzymes, free radicals production and activation of Phospholipase A2. The phospholipase releases arachidonic acid which again attenuates re-uptake of
glutamate, thus producing the vicious circle of excitotoxicity.
Figure 4.  “Direct” and “indirect” effects of reactive oxygen species (ROS). Reactive oxygen species directly interact with DNA, proteins and lipids and
destroy them through oxidation process causing cell death (direct effect). High concentration of ROS damage structure and function of mitochondria and
change the redox state of the cell interior (indirect effect). Damage to the mitochondria leads to release of factors initiating process of programmed cell
death (apoptosis). Oxidative stress activates transcription factor NFkB (nuclear factor kB), which induce synthesis many proinflammatory cytokines and
adhesion molecules. Increased expression of cytokines and adhesion molecules augments inflammatory process in neural tissue.
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Based on these facts three very important conclusions should
be drawn which are relevant for clinical practice. First, there is no
perfect relation between clinical signs and severity of intracranial
hypertension; second, monitoring of ICP is extremely important to
gauge the risk of herniation; and third, maintaining CBF is the
highest priority measure to treat patients with intracranial hyper-
tension. Thus, close monitoring of CBF is extremely important when
taking care of patients with intracranial pathology.
Chronic hypoperfusion and investigations
of cerebral blood flow regulation
In patients with impaired CA even slight fluctuations in ABP
may lead to cerebral ischemia or encephalopathy due to global or
local hyperperfusion [76]. In such patients ischemia is the result
of a combination of chronic and acute factors. Typically slowly
progressive narrowing of the large cerebral artery leads to drop in
local CPP. The perfusion deficit is most marked at the regions
farthest from the main supplying arteries — the arterial border
zones [76] — at the margins of the territories supplied by the an-
terior, middle, and posterior cerebral arteries or between the cor-
tical vessels and small penetrating arteries at the base of the brain.
The baseline drop in CPP makes these areas susceptible to fluc-
tuations in systemic ABP, oxygen supply, and local vascular re-
sistance. When the drop in perfusion is of short of duration, tran-
sient neurological deficits may occur, but when the CPP falls be-
low critical levels for a sufficient duration, infarction will result. Thus,
it is important to know in advance whether a patient is at high or
low risk of brain infarct caused by hypoperfusion alone.
In disease states, produced for instance by marked arterial
narrowing, the peripheral microvessels are maximally dilated, and
a decrease in CPP results in a decrease of CBF. With mild de-
creases in CPP, cellular function is maintained by increased oxy-
gen and nutrient extraction (called often as stage II) [77]. As CPP
falls further, oxygen extraction reaches a maximum, and any de-
crease in CBF are accompanied by decreased oxygen consump-
tion (referred to as “stage III”). When critical levels of oxygen and
nutrient delivery cannot be met, cell death occurs.
Two main approaches to predict the risk of cerebral infarction
due to drop of CPP are employed. One is to make quantitative
measurements of oxygen extraction, oxygen consumption and
CBF. In practice, such measurements can be made using positron
emission tomography (PET) with 15O2 and C
15O2. An area with ex-
hausted cerebrovascular reserve will show relatively decreased
CBF and increased fractional oxygen extraction. Other methods
of assessment of CA on the basis of measurements of oxygen
extraction rate include arterio-venous O2 difference and near-in-
frared spectroscopy. The second most often used approach is to
measure the response of local CBF to a physiology challenge,
such as pharmacologic vasodilatation, elevated CO2 level, and
a challenge with decreased ABP.
Perfusion imaging becomes a standard part of stroke imag-
ing to determine the ischemic penumbra in patients with ischemic
stroke. In case of chronic perfusion impairment, however, a single
CBF or blood volume measurement is rather not adequate. First,
interpretation of any single perfusion measurements is difficult
because of the high physiological variability of CBF. Second, the
relationship between absolute CBF and progression to infarction
varies widely between and within patients. This is particularly im-
more sensitive to ischemia than to pressure. It has been shown
that neurons can withstand pressure several times higher than
the atmospheric pressure [70].
Decrease in CPP lowers intraluminal ABP and leads to dilata-
tion of arteries through the vasogenic mechanism. Furthermore,
excessive buildup of CO2, potassium ions, and adenosine add to
the effect of hypoxia resulting from insufficient CBF to cause va-
sodilatation. Unfortunately, at this point, even significant vasodila-
tation does not help much improving CBF. Increased ICP con-
stricts cerebral veins and is transmitted through their thin, compliant
walls so that the point of maximal resistance of cerebral vascular
bed shifts from arterial to venous system [71]. In other words,
CBF decreases because of a lower and lower pressure gradient
between arterial and venous system. High pressure in venous
system decreases venous outflow and leads to congestive brain
swelling.
Under these conditions, general cerebral vasodilatation has
even more deleterious effects. Dilated arteries contain more blood
and increased cerebral blood volume further increases ICP. More-
over, maximal arterial dilatation profoundly decreases stiffness of
arterial walls, which become good transmitters of intraluminal ABP
into the brain parenchyma [70]. Thus, increased cerebral blood
volume, the transmission of intraluminal ABP into brain parenchy-
ma, as well as decreased venous outflow are main determinants
of ICP increase. In this situation, the dynamic system consisting
of intracranial cavity and its contents loses its compliance and
becomes “stiff” so that even small additional volume of systolic
blood surge leads to huge ICP increase [72]. When ICP reaches
the level of ABP, CPP decreases to zero leading to complete ces-
sation of CBF. It will restart only if ABP rises sufficiently beyond
the ICP to restore CBF. If this fails to occur, brain death occurs.
When the homodynamic disturbances caused by pathologic
intracranial volume overcome physiologic mechanisms of intrac-
ranial volume compensation, ICP not only increases but also ran-
dom ICP fluctuations begin to occur more frequently. Statistical
analysis of these fluctuations has allowed pattern descriptions
specific for increased ICP [73, 74]. These fluctuations are called A
waves of Lundberg. A waves are characterized by a rapid rise in
ICP up to 50–100 mmHg which is followed by a variable period
during which the ICP remains elevated and then a rapid fall to
baseline. These waves are also called “plateau” waves. It should
be mentioned that when A waves occur, the baseline level of ICP
is already elevated. Plateau waves develop as a result of a rapid
increase in intracerebral blood volume, when sudden decreases
in CPP leads to vasodilatation. Thus, plateau waves occur in pa-
tients with intact CA and reduced intracranial compliance. These
sudden transient drops in CPP may be triggered by many, often
poorly characterized factors. A well known trigger of A waves is
postural change. The increase in CPP required to abort plateau
waves may be generated by the Cushing phenomenon, which is
activated when brainstem ischemia triggers systemic hyperten-
sion, thus increasing CPP [75]. During plateau waves, patients
may have severe headache, visual disturbances, impairment of
postural or motor control, altered consciousness, bradycardia and
high ABP. The last two symptoms are caused by activation of
Cushing reflex in effort to preserve CBF. However, in many pa-
tients plateau waves may not cause these symptoms and brain
stem herniation ensues with minimal warning signs.
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portant in assessing chronic rather the acute hypoperfusion, be-
cause the degree of flow decrement is generally of the same or-
der as that from the physiological sources of variability [78]. Third,
absolute perfusion measurements can be inaccurate because the
models used to derive CBF are not sufficiently accurate. This prob-
lem is most significant in methods that depend on intravascular
tracers. With these methods, a perfusion value is assigned from
model-dependent calculations based on the dispersion of a trac-
er [79]. Regional perfusion, however, is only one of the factors
that can affect this dispersion. An additional important factor is
intravascular dispersion arising from convection and diffusion
during bulk flow in the large arteries between the heart and the
capillaries. This intravascular dispersion may vary substantially and
depend on the degree of turbulence within the vessels and on the
path length to the tissue of interest. Because this dispersion has
effects on the tissue concentration versus time function that are
similar to variation from capillary flow, variation in turbulence or
path length will produce artifactual changes in the value obtained
for tissue perfusion. Despite of these limitations assessment of
absolute CBF is important, because an absolute decrease in CBF
may help to identify the “steal” phenomenon.
The assessment of CA is free of the above mentioned limita-
tions. It can be evaluated by measuring relative blood flow chang-
es in response to the change in the blood pressure using “static”
or “dynamic” approaches [80]. Both approaches attempt to es-
tablish whether CA is normal or impaired, using the autoregulato-
ry curve of CBF in humans as a model [81, 82]. In the static meth-
od, evaluation of CA is performed under steady-state conditions.
That is, a first measurement of CBF obtained at a constant base-
line ABP is followed by another steady-state measurement that is
taken after the autoregulatory response to a change in ABP has
been completed. If the change in ABP (within the lower and upper
limits of CA estimated for healthy humans) does not change CBF,
CA is functioning properly. If manipulation of ABP evokes signifi-
cant changes in CBF, the CA is impaired. In the static method,
manipulation of ABP is usually achieved using vasoactive drugs.
Static methods evaluate the efficiency of the CA, that is overall
change in cerebrovascular impedance induced by changes in ABP.
Dynamic methods use rapid changes in ABP and analyze CBF
and ABP during the whole autoregulatory process [80]. Systemic
hemodynamic changes may be induced using rapid leg cuff de-
flation, progressive lower body negative pressure, Valsalva ma-
neuver, deep breathing, ergometric exercise or head-down tilting.
Dynamic methods are able to assess both efficiency and latency
of CA response, that is overall change in CVR as well as the time
in which the change in the CVR is achieved.
The use of systemic hypotension to challenge the CA response
is limited, however, because pharmacologically induced hypoten-
sion could result in permanent ischemic injury, in particular in pa-
tients with already insufficient CBF. Balloon test occlusion itself is
a focal challenge to CPP; but it is rather more important to know
whether current flow is adequate than in the effect of complete
occlusion. What is needed is a mild global challenge to cerebral
perfusion that is unlikely to produce ischemia. Two methods of
physiological challenge that meet these criteria and that have re-
ceived substantial study for testing CA include a test with admin-
istration of acetazolamide and systemic partial CO2 pressure
manipulations.
Acetazolamide is a carbonic anhydrase inhibitor that acts as
a potent cerebral vasodilator. Administered intravenously, it slow-
ly penetrates the blood-brain barrier, where it reversibly inhibits
the carbonic anhydrase in brain parenchyma. Carbonic anhydraze
catalyzes the conversion of bicarbonate and hydrogen ion to wa-
ter and CO2. Acetazolamide decreases the production of bicar-
bonate and results in a decrease in the extracellular pH in the
brain [83, 84]. This induced acidosis results in vasodilatation of
small arterioles [85, 86]. Acetazolamide administration thus in-
duces a considerable increase in CBF [86]. Doses used in the
assessment of cerebrovascular reserve are in the 15–18 mg/kg
range; in many studies a standard total dose of 1 g is used [87].
Systemic ABP, HR and respiratory rate are unaffected [88]. The
effect on CBF may be seen within the first 5 minutes after admin-
istration, and steal phenomenon is most conspicuous at about 5
minutes [89]. Peak CBF augmentation occurs at approximately
10 minutes after bolus intravenous administration and diminishes
little over the next 20 minutes. With these dose parameters, a 30%
to 60% increase in CBF is achieved in normal subjects [90]. This
response is little diminished in the healthy aged population [91].
The percentage increase in CBF after acetazolamide administra-
tion may be used to define cerebrovascular reserve based on the
following formula:
Cerebrovascular reserve = (CBFpost – CBFpre)/CBFpreacetazolamide
Although a global increase in CBF by about 30% is accepted
as normal, a variety of criteria have been used to define an abnor-
mal response to acetazolamide. The definition has varied among
the major studies in which it was used, including such criteria as
greater than 5% decrement in absolute CBF, a less than 10% in-
crement in absolute CBF, an absolute change of less than 10 mL/
/100 g/min, and a value greater than two standard deviations be-
low control values.
The bolus administration of acetazolamide over several min-
utes at these doses is generally well tolerated. The most com-
monly reported side effects of intravenous administration include
transient perioral numbness, paresthesias, and headaches [88].
The theoretic concern of induced ischemia as results of the “steal”
phenomenon has not been borne out by clinical experience [90].
Manipulation of arterial CO2 tension (PaCO2) has also been
used to test cerebrovascular reserve. Low level hypercarbia re-
sults in a reproducible increase in CBF of 0.01–0.02 mL/g/min for
each 1 mm Hg rise in PaCO2. The effect is rapid and quickly re-
versible. It is mediated through a change in extracellular pH as
well as NO and cyclic guanosine monophosphate and results from
changes in vascular smooth muscle tone [92]. CO2 manipulation
has been performed with a number of schemes, including breath
holding or hyperventilation, rebreathing, and inhalation of 3% to
5% CO2. The effect of altered CO2 tension on CBF has been quan-
tified either as a fixed effect for particular CO2 manipulation (sim-
ilar to the quantification of acetazolamide effect) or as the slope of
the CO2 — CBF relationship according to the formula [93]:
Cerebrovascular reserve = [(CBFpost- CO2 – CBFpre- CO2)/
/(CBFpre-CO2)] ¥ [100/(Papre- CO2 – Papost- CO2)]
In clinical practice, the magnitude of CBF changes is smaller
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than that achieved with acetazolamide. The average increase in
cerebrovascular reserve (percentage change in blood flow per
mm Hg change in PaCO2) is 1.1% to 2.9%. With 5% CO2 inhala-
tion, the CBF response is approximately half of the response to
acetazolamide. Furthermore, although CO2 manipulation and ac-
etazolamide in theory both produce vasodilatation and alter CBF
in similar fashion, the correlation between CBF changes produced
by the two has varied from poor to moderate [94–96]. CO2 ma-
nipulation also has the disadvantage of itself altering systemic
ABP — mean ABP increase of about 10 mm Hg with 5% CO2
— an effect that may blunt the CBF response [94]. However, CO2
manipulation is easily performed, generally well tolerated, and has
no long-term effects. The rapid response to CO2 makes it particu-
larly suitable for transcranial Doppler (TCD) measurements.
An important phenomenon affecting the results of CA testing
is that of “steal”. In regions under stage II or III conditions, it is
common to observe a decrease in CBF after vasodilator adminis-
tration [90, 97]. This phenomenon is created by the interaction
between regions of different cerebrovascular response and the
systemic effects of the agents used for physiologic or pharmaco-
logic challenge. Areas with proper CA will show vasodilatation,
lowering the pressure in the larger blood vessels supplying both
normal and abnormal areas. This lower pressure results in a drop
in blood flow in the regions that are already maximally dilated.
In assessment of CA spatial and temporal resolution (the de-
gree of CA impairment can be regionally and tissue specific), si-
multaneous imaging of parenchymal and vascular structures (sta-
tus of parenchyma and large arteries is important in interpretation
of autoregulatory test's results), invasiveness, cost and availabili-
ty should be taken into account when one selects a testing tech-
nique.
Physiological techniques to assess functionality of CA
Physiological techniques include TCD, perfusion CT (pCT) and
MR (pMR) imaging with dynamic contrast bolus administration,
arterial spin-labeling MR perfusion (ASL MR), blood oxygenation
level-dependent MR imaging (BOLD). More invasive techniques
such as positron emission tomography (PET), single-photon emis-
sion CT, and Xenon CT are not reviewed here.
Transcranial Doppler ultrasonography (TCD)
The most popular technique used to assess CA using both
static and dynamic methods is the measurement of blood flow
velocity (CBFV) changes in cerebral arteries with TCD. Implemen-
tation of this technique is based on the fact that changes in CBF
will be reflected by changes in CBFV. If CA is intact, drop or in-
crease in ABP will not affect CBFV. This is because any change in
ABP will be compensated by adequate change in diameter of small
resistance arterioles. Thus, CPP, CBF and CBFV will remain un-
affected.
Many investigators tried to formulate objective criteria to clas-
sify CA usually as normal/impaired using different approaches.
For static methods, most commonly used measures of CA are
correlation coefficient (r) between CBF and mean ABP as well as
“index of static autoregulation” (aARi), which is expressed as
a ratio of percentage change in CVR to percentage change in
ABP (sARi = %CVR/%ABP) [98, 80]. The percentage change in
CVR is calculated as the ratio of ABP to CBF (CVR = ABP/CBF).
For perfect CA, correlation coefficient would equal 0 and aARi
would be 1, while complete lack of CA would yield r and sARi of
1 and 0, respectively. Most commonly proposed threshold be-
tween normal and impaired CA for both r and sARi is 0.5 [98, 99].
Evaluation of CA in dynamic methods is based on “dynamic CA
index” (dARi). This is the dynamic equivalent of sARi and is de-
fined as dARi = (DCVR/DT)/DABP, where DT is the time when CA
response occurs [100, 80]. Thus, the dynamic CA index evalu-
ates not only overall change in CBF induced by change in ABP,
but also quantifies time-dependence of the CA response. A value
of dARi = 0 represents the absence of CA, while value = 9 corres-
ponds to a very efficient CA response. The proposed threshold
value between normal and impaired CA is about 5 [80, 101]. Static
and dynamic methods of evaluation of CA yield similar results [80].
TCD can only measure velocities in large arteries. Regional
areas of impaired CA in an artery distribution may be missed when
averaged with areas that are better perfused. Furthermore, corre-
lation between flow velocities and CBF is weak in some patients,
mostly because of collateral circulation [102, 103]. Also, TCD can
not be performed in some patients due to absence of acoustic
windows [104].
Perfusion CT and MR imaging with dynamic contrast
bolus administration
The use of this technology for acute stroke evaluation is in-
creasing. The bolus is tracked during the passage through cere-
bral circulation in order to calculate cerebral blood volume and
CBF using models that are less robust than those used for freely
diffusible tracers [105, 106]. In assessment of CA, however, this
problem is minimized as preacetazolamide study serves as a con-
trol for postacetazolamide study, both can be performed at one
session. The spatial resolution is high and the flow data can be
easily mapped to the anatomic images. Furthermore, MR or CT
angiography can be performed at the same time. The radiation
dose, limited coverage of the brain and allergic reaction for con-
trast are disadvantages of the CT perfusion, whereas in MR perfu-
sion is difficult to obtain reliable absolute quantitation because of
the complex relationship between concentration and signal.
CT perfusion has received limited but promising use in assess-
ment of CA [107, 108]. The experience with MR perfusion is more
extensive and promising [109, 110].
Arterial spin-labeling MR perfusion (ASL MR)
Experience with this method in evaluation of CA is limited. The
effect of magnetic saturation or inversion of the protons in arterial
blood on the MR signal is used to derive quantitative CBF mea-
surements. This technique does not require exogenous contrast
and provides good spatial resolution and repeatability. However,
signal-to-noise ratio is poor, and imaging times of 3-6 minutes
have been needed to obtain satisfactory results for even single-
slice imaging. Though water is a diffusible tracer, the arterial tran-
sit time and limited diffusibility of water have effects on CBF mea-
surements with this technique [111], a particular important prob-
lem when studying patients with chronic cerebrovascular disease.
Experience is limited, but expected and reproducible CBF chan-
ges are seen when the technique is applied, in conjunction with
acetazolamide or CO2 manipulation, to healthy adults [111, 112],
and those with cerebrovascular disease [113]. A study showed
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that ASL MR imaging with acetazolamide challenge produced re-
sults comparable to those of 123I-IMP SPECT in patients with arte-
rial stenosis [114].
Blood oxygenation level-dependent MR imaging (BOLD)
BOLD imaging, used primarily for functional activation stu-
dies, has been applied to assess CA, despite the BOLD does not
measure CBF directly. BOLD exploits the magnetic susceptibility
differences between oxidative measures of regional oxygenation.
The BOLD signal depends on several factors, including local CBF,
cerebral blood volume, oxygen delivery, oxygen consumption,
hemoglobin level, and pH [115]. BOLD signal has been shown
also to change in response to CO2 alteration or acetazolamide
challenge, although there is substantial variability in the response
[116–118]. The same maneuvers that increase CBF generally re-
sult in an elevated regional relative proportion of oxy-hemoglobin.
However, the effects of these challenge maneuvers in the setting
of chronic flow impairment are not well established. Complex in-
terplay exists between the physiological factors listed earlier, and
BOLD signal will depend heavily on the degree and timing of the-
ses changes. Limited studies demonstrated BOLD imaging res-
ponse to vasodilatory challenge in patients with CA impairment
[115, 118–120]. The response correlated moderately with SPECT
response after acetazolamide [115], however, the response did
not reliably match the TCD response [120].
Positron emission tomography (PET)
PET methods, which are used to assess CA, vary depending
on the technique [121]. In general PET employs the juxtaposed
measurement of CBF and oxygen extraction to determine wheth-
er perfusion pressure has fallen below levels where the oxygen
demand of tissue can be met by changes in cerebrovascular re-
sistance rather than measure the vascular response to a pharma-
cologic or physiologic challenge. Theoretically, an increased oxy-
gen extraction fraction should correspond to the level where cere-
brovascular resistance is depleted when assessed by a challenge
test. In practice, however, it has been shown that these two mea-
sures are strongly related but not the same [93, 122]. Although
oxygen extraction fraction has been chosen by some as the mea-
sure of choice for CA [123], it remains to be seen whether the
oxygen extraction fraction or pharmacologic challenge of CA is
superior in identifying patients at high risk of stroke.
In clinical practice, PET has disadvantages that currently limit
its application. PET measurements require isotopes, chiefly 15O,
with a very short half-life; it therefore requires an on-site cyclotron.
The availability of this equipment is limited. PET studies of the
reserve are cumbersome and expensive, thus they are used more
in clinical research than in routine practice. The spatial resolution
of PET has improved substantially, but the studies still require long
acquisition times and are sensitive to patient motion.
Single-photon emission CT (SPECT)
SPECT has been used in conjunction with several radiophar-
maceutical agents to measure CBF and test cerebrovascular re-
sistance [124]. These agents include technetium-99m-hexame-
thyl-propylenamine oxime (99mTc-HMPAO), 99mTc-ethylene cysteine
dimmer (99mTc-ECD), and N-isopropyl-[iodine-123]-iodoamphet-
amine (123I-IMP). They are extracted by the brain in proportion to
local CBF. They have a long half-life, measured in hours, which
allows time separation of injection and imaging long enough to
obtain high signal-to-6noise images. The assessment of CA with
these agents can be performed with both qualitative and quanti-
tative CBF measurements. The qualitative methods are less ex-
pensive and more simply performed but only allow assessment
of relative CBF (i.e. comparison of the two hemispheres or com-
parison of cerebral hemispheres with cerebellum). Although the
presence of impaired CA can be detected by these methods [125,
126], the results vary substantially [127], and have compared
unfavorably with quantitative methods of flow assessment [128,
129]. These results are probably due in part to the fact the qualita-
tive assessment of CA does not permit direct detection of the
“steal” phenomenon. A degree of quantitation has been achieved
with 123I-IMP using a single arterial blood sample [129, 130]. With
this method, it has been shown that acetazolamide-induced CBF
change measured with these agents correlates with quantitative
CBF response [129].
SPECT, performed with these agents, has several disadvan-
tages that limit its clinical use. The long half-life of the injected
agents necessitates either a several-day delay between the pre-
and postacetazolamide studies, the use of different radiophar-
maceuticals, or the use of only a small tracer does for the pre-
acetazolamide study; each of theses machinations introduces
potential errors when the two studies are compared. Imaging time
itself is long. The nominal spatial resolution of SPECT studies is
inferior to that of the other imaging modalities, and co-registration
with CT or MR imaging is needed when intrahemispheric variabil-
ity in CA is observed.
SPECT has also been performed with xenon-133 (133Xe),
a rapidly diffusible, inert radiotracer that is delivered by inhalation
[131]. This method produces a quantitative CBF measurements
[132, 133]. Although it is free of some of the difficulties of the
injectable SPECT agents, the imaging times are long, and the
spatial resolution is even less than that achieved with the other
agents. Furthermore, the substantial attenuation of the low-ener-
gy gamma article emitted degrades the imaging of deep struc-
tures.
Xenon CT
Xenon CT also provides quantitative assessment of CBF and
CA [90]. An approximately 70:30 mixture of oxygen and non-ra-
dioactive xenon gas is delivered by inhalation for several minutes,
and serial CT scans are acquired. Because the X-ray attenuation
of xenon exceeds that of cerebral tissue, the accumulation of this
tracer can be measured over time. Using the Kety-Schmidt mod-
el, CBF can be delivered from this time course of oxygen accu-
mulation over 5 to 6 minutes. This method provides reliable CBF
quantitation [128] combined with high-resolution imaging meth-
ods [128, 134]. Although xenon inhalation at these concentrations
is itself known to increase CBF after several minutes, the phe-
nomenon has minimal effect with well-designed protocols [135].
The study can be performed before and after acetazolamide ad-
ministration in the same session, because the xenon washes out
of the brain rapidly.
These qualities make xenon CT well suited for assessment of
CA, and this technique has received substantial clinical use and
study. It has been validated against the “golden” standard mea-
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sures of CBF [106] and correlates with PET-derived oxygen
extraction fraction [136].
However, few centers have developed the expertise neces-
sary to perform these studies successfully. Although xenon CT is
usually well tolerated at the concentrations used for these stud-
ies, feelings of inebriation, somnolence, or dysphoria may occur
and interfere with the study [135]. The technique is sensitive to
head motion, and it can be difficult to maintain immobility for the
duration of combined pre- and postacetazolamide imaging.
Clinical applications of autoregulation testing
Risk assessment of cerebral infarction
Autoregulatory response can predict stroke in some types of
cerebrovascular disease. Patients with symptomatic occlusion of
a major cerebral artery have eight times greater relative risk of
cerebral infarction in the affected territory if they have evidence of
diminished CA response [133, 137]. Some studies that included
patients with severe stenosis have shown significantly increased
incidence of cerebral infarction in those with impairment of CA
[138–140].
Selection of patients for extracranial to intracranial
bypass surgery
Despite a multicenter extra- to intracranial (EC-IC) bypass trial
found no benefits from the procedure in patients with symptomat-
ic stenosis or occlusion [141], it is likely that benefits can be
achieved if selection was confined to patients with impaired CA
and in whom thromboembolic infarction was excluded [123]. Sev-
eral studies showed clinical benefits associated with improvement
in CA response after surgery [96, 142–144].
Testing of CA in patients with Moya-moya disease appears to
be particularly useful, because multiple severe proximal intracra-
nial stenoses with subsequent extensive collateral circulation usu-
ally develop. Areas with impaired CA are at high risk of infarction,
especially in children. Surgical revascularization procedures are
often performed, after which dramatic improvement in CA response
correlated with cessation of ischemic events has been demon-
strated. The development of new vessels from the grafts occurs
more reliably in areas of impaired CA, independent of local CBF,
suggesting that impaired CA results in greater local angiogenic
drive [145, 146]. Testing of CA is therefore likely to have an impor-
tant role in selecting patients for revascularization and for the guid-
ance of graft placement.
EC-IC bypass can also result in improved cognitive function
in patients with impaired CA [147]. A large, randomized trial to
assess effectiveness of EC-IC bypass in eligible patients with CA
impairment as assessed using PET is under way [123].
Assessment of CA in conservative patients management
In patients with impaired CA the primary goal is to maintain
adequate CPP, by optimization of cardiac function, minimizing
orthostatic fluctuations of ABP, and limitations of antihyperten-
sive medication. If CA is intact, emphasis may be placed in-
stead on minimizing hypertension and avoiding thromboem-
bolism. The relative merits of surgical and aggressive medical
treatment for impaired CA, however, remain largely unstudied,
as CA function can improve over time without surgical revascu-
larization [137, 148]. In some patients temporizing with medi-
cal therapy for months to several years may allow the formation
of sufficient collateral circulation to remove the risk of stroke
from hypoperfusion.
Assessing risk of hyperperfusion syndrome
Hyperperfusion syndrome is a rare but disastrous complica-
tion of carotid endarterectomy. Hyperperfusion, defined as in-
creased CBF after surgery, results in cerebral edema and intrace-
rebral hemorrhage [149, 150]. The prognosis is poor, with mortal-
ity of 36% to 63%, and survivors have significant morbidity. If pa-
tients at risk for the syndrome can be identified preoperatively,
strict control of ABP can be instituted in the early postoperative
period [149, 151]. Assessment of CA can help to identify patients
at risk for this phenomenon as postoperative hyperperfusion was
seen only in patients with impaired CA (< 10% CBF response
after acetazolamide) [152].
Balloon test occlusion
Balloon test occlusion of the internal carotid artery is per-
formed to assess the adequacy of collateral circulation before
permanent carotid artery occlusion. Most patients who tolerate
20 to 30 minutes of the occlusion without developing neurologi-
cal deficits can safety undergo permanent occlusion [108]. How-
ever, approximately 10% of patients, who pass the clinical eval-
uation, suffer ipsilateral cerebral infarction after permanent oc-
clusion. Several measures have been used to increase the sen-
sitivity of balloon test occlusion, including pharmacologically in-
duced hypotension, stump pressure measurements, and perfu-
sion imaging; no consensus exists on the optimal protocol. Test-
ing of CA has a strong theoretic advantage over mere CBF im-
aging for the same reasons that it provides superior evaluation
in chronic cerebrovascular disease. Testing of CA with aceta-
zolamide challenge has been performed during balloon test oc-
clusion with promising results [108, 153].
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